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Abstract: The global burden of chronic obstructive pulmonary disease (COPD) continues to 
grow in part due to better outcomes in other major diseases and in part because a substantial 
portion of the worldwide population continues to be exposed to inhalant toxins. However, 
a disproportionate burden of COPD occurs in people of low socioeconomic status (SES) due to 
differences in health behaviors, sociopolitical factors, and social and structural environmental 
exposures. Tobacco use, occupations with exposure to inhalant toxins, and indoor biomass fuel 
(BF) exposure are more common in low SES populations. Not only does SES affect the risk of 
developing COPD and etiologies, it is also associated with worsened COPD health outcomes. 
Effective interventions in these people are needed to decrease these disparities. Efforts that may 
help lessen these health inequities in low SES include 1) better surveillance targeting diagnosed 
and undiagnosed COPD in disadvantaged people, 2) educating the public and those involved 
in health care provision about the disease, 3) improving access to cost-effective and afford-
able health care, and 4) markedly increasing the efforts to prevent disease through smoking 
cessation, minimizing use and exposure to BF, and decreasing occupational exposures. COPD 
is considered to be one the most preventable major causes of death from a chronic disease in 
the world; therefore, effective interventions could have a major impact on reducing the global 
burden of the disease, especially in socioeconomically disadvantaged populations.
Keywords: health disparities, COPD, interventions, prevention, management, international, 
socioeconomic status
Introduction
Health disparities are a major contributor in chronic obstructive pulmonary disease 
(COPD) around the world.1,2 COPD is not unique, as health disparities are found with 
other chronic diseases and throughout the continuum of care. However, the influence 
of health disparities and socioeconomic status (SES) on the etiology and outcomes of 
major noncommunicable chronic diseases is more evident with COPD. Environmental 
risk factors for developing COPD are more common in low SES people, which include 
tobacco smoking, environmental tobacco smoke (ETS), indoor and outdoor air pol-
lution, and biomass fuel (BF) exposure.1 Furthermore, genetic tendencies for asthma3 
and nicotine addiction4 may contribute to disparities in COPD since some race/ethnic/
tribal groups are overrepresented in low SES stratum in different countries. According 
to the World Health Organization (WHO), .90% of COPD deaths occur in low-
income and middle-income countries (LMICs).5 In an effort to reduce the magnitude 
of COPD in populations that bear a disproportionate burden of disease, initiatives by 
national and international organizations are presently targeting disparities in respira-
tory diseases. Continuity in disease prevention and delivery of health care as well as 
access to appropriate medications for COPD needs to be provided to all segments of 
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the population, particularly the disadvantaged. This article 
provides perspective on the health disparities related to SES 
in COPD and strategies that may help in efforts to provide 
quality health care in this population.
Methods
We conducted systematic searches of the literature in English 
or articles with English abstracts using bibliographic data-
bases of PubMed/Medline (National Library of Medicine 
and National Institutes of Health), Embase, and the Cochrane 
database. We used the keywords “COPD” or “emphysema” 
or “chronic bronchitis”, “socioeconomic status”, “poverty”, 
“health disparities”, “prevalence”, and “outcomes”.
Definitions of health disparities 
and SES
For all chronic diseases, multiple socioeconomic factors 
contribute to health disparities including income, education, 
residential segregation, genetic susceptibility, stress, access 
to health care, social and physical environment, and employ-
ment. Unequal access to quality health care is the foundation 
of health disparities. However, in general, health disparities 
are not only a function of whether an individual can afford to 
buy goods and services that aid good health but also include 
health behaviors related to lifestyle and the environment. 
Unhealthy behaviors such as tobacco smoking often provide 
pleasure and relaxation that help regulate mood,6 particularly 
in low SES people who have significant stressors in life.
Disparities exist when differences in health outcomes 
or health determinants are observed between populations. 
A number of organizations have defined health-related dis-
parities including the WHO,7 the United States (US) Office of 
Disease Prevention and Health Promotion,6 and international 
pulmonary organizations such as the American Thoracic 
Society (ATS), and European Respiratory Society (ERS).8 
The WHO defines health disparities as:
Inequalities that exist when members of certain population 
groups do not benefit from the same health status as other 
groups. Further, these disparities occur in the provision of 
healthcare and access to healthcare across different racial, 
ethnic and socioeconomic groups.7
In Healthy People 2020, the US Office of Disease Preven-
tion and Health Promotion describes disadvantaged popula-
tions as:
Groups of people who have experienced greater obstacles 
to health based on their racial or ethnic group; religion, 
SES, gender, age, occupation, mental health, cognitive, 
sensory or physical disability or other characteristics linked 
to discrimination or exclusion.6
A joint 2013 ATS/ERS committee published a policy 
statement broadly defining disparities in respiratory health 
similar to the Healthy People 2020 definition – specifically 
“significant differences in respiratory health that are closely 
linked to racial ancestry, social, economic and/or environ-
mental differences”.8
SES is a composite assessment of a person’s economic 
and social position in a society based on several factors 
including income, occupation, home and neighborhood 
environment, and educational attainment. These factors 
are correlated, and it is difficult to identify the independent 
contribution of each factor on the composite assessment of 
SES. However, many investigators use a single component of 
SES, for example, educational attainment or annual income, 
to represent a person’s overall economic and social position 
in their country. In studies evaluating the SES, education 
is often defined by years of educational attainment (ie, less 
than high school (secondary school), high school (secondary 
school graduate), some college/university, or college/
university graduate.
Income is usually defined by individual annual income 
or cumulative household income. Since the median annual 
income varies widely between countries, the income-based 
definition of “low SES” can also vary widely across the 
globe. The WHO defines extreme poverty as an individual 
income less than or equal to the equivalent of 2.00 US dollar 
(USD) per day.9 The United Kingdom, like most of the 
developed world, defines poverty as 60% of median income 
in a country. However, in the US, poverty is defined by the 
US Census Bureau by comparing income to be three times 
the cost of a minimum food diet in 1963, which is updated 
annually for inflation and adjusted for family size, compo-
sition (ie, number of adults and children in a household), 
and age of householders.10 For example, in 2014, the US 
poverty level for a family of five persons was ~29,000 USD 
annual income, which was 53.7% of the 54,000 USD median 
household income.
Other infrequently used measures of SES include 
geographical area deprivation which categorizes neighbor-
hoods by global positioning system and median income; 
number of persons living in household; and occupation (eg, 
manual labor in industry, service industry, office worker, 
agricultural worker, housewife, professional worker, and 
machine operator).11
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Health disparities in respiratory 
diseases
Health disparities are more commonly seen for respiratory 
diseases. The lowest socioeconomic groups are up to 14 times 
more likely to have respiratory disease than the highest 
group.8 An individual’s socioeconomic position usually has 
continuous and numerous health effects that accumulate over 
a lifetime, and these long-term environmental exposures 
lead to diseases such as COPD. Disparities related to SES 
are evident for a number of respiratory diseases including 
asthma, COPD, lung cancer, and respiratory tract infections 
such as tuberculosis.8 Lung cancer is clearly more likely to 
occur in people of low SES, even when adjusting for tobacco 
use.10 In some countries, treated tuberculosis is a relatively 
common cause of COPD in people of low SES living in 
low-income, multiple person dwellings.1
Compared to other common causes of morbidity and 
death, COPD appears to be more socioeconomically related 
than others. In a study considering various causes of death, the 
association was stronger for COPD than cardiac disease.11 
This is principally true because smoking and environment 
play leading roles in lung disease development – and people 
of lower SES tend to have substantially greater exposures 
to both of these factors. Although asthma affects all ethnic 
groups, suboptimal outcomes are disproportionately shared 
by certain minority groups and economically disadvantaged 
persons.12,13 However, low income has a greater influence on 
COPD prevalence than on asthma prevalence,14 this may be 
because asthma is more genetically driven whereas COPD 
is more environmentally induced.
According to the WHO, the social determinants of 
health are mostly responsible for the health inequities seen 
within and between countries.15 The WHO defines social 
determinants of health as the conditions in which people 
are born, grow, work, live, age, and the wider set of forces 
and systems shaping the conditions of daily life. Whitehead 
described the principal determinants of health disparities 
arising from multiple sources; Table 1 provides the correla-
tions relative to COPD.16
Health disparities in COPD
As shown in Tables 2–4, there is a strong relationship 
between COPD and SES.17–58 Environmental factors 
contributing to the development or worsening of COPD 
include use of tobacco products, occupation, prenatal 
and childhood exposures, respiratory tract infections, air 
pollution, and housing conditions including the use of 
BF, all of which are more likely to be present in low SES 
people. In developed countries, the major risk factor for 
COPD is long-term tobacco product use, whereas in less 
developed countries, the conditions of the home (BF) and 
work setting (dust, fumes, and vapors) often have a more 
substantial impact on health than either personal position 
in society or tobacco exposure. Consistent with this, a 
multinational study from the 1970s and 1980s showed 
there was a poor correlation between COPD mortality 
and cigarette smoking data among 31 countries.59 More 
recently, the Burden of Obstructive Lung Disease (BOLD) 
study showed a better correlation of COPD prevalence and 
tobacco use; however, the relationship was not strong in 
all settings.60
SES and respiratory symptoms
One would expect that if SES is a risk factor for develop-
ing COPD, it would also increase the risk of respiratory 
symptoms. Studies over the last 2 decades have shown 
that people of low SES exhibit lower lung function and 
more respiratory symptoms than those in higher SES 
groups – typically at least a several-fold difference 
(Table 2). Whether using forced expiratory volume in 
Table 1 Whitehead’s principal determinants of health disparities and COPD correlates
General determinants of health disparities Corresponding determinants for COPD
Natural biologic variation Genetic susceptibilities
Health-damaging behavior of individuals Smoking tobacco and/or biomass fuel use
Transient health advantage for people who adopt new  
behaviors first
Educated people making behavioral changes more readily than those with 
lower levels of education
Health-damaging behavior in which the degree of choice  
of lifestyles is severely restricted 
People being born into and remaining in impoverished and low education 
settings
Exposure to unhealthy living and working conditions Exposure to environmental (second-hand) smoke and indoor biomass fuels
Inadequate access to health care People in lower socioeconomic status and having less health care access
Natural selection leading to the tendency for the sick  
to move down the social hierarchy
People with advanced COPD become disabled due to disease 
Note: Data adapted from Whitehead M. The concepts and principles of equity and health. Health Promotion Int. 1991;6:217–228.16
Abbreviation: COPD, chronic obstructive pulmonary disease.
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1 second (FEV
1
), the presence of airflow obstruction (AO), 
or respiratory symptoms, all the studies show more impair-
ment in people with low SES and whether it is based on 
income, education, or occupation.
SES and COPD prevalence
Table 3 shows studies of the relationship between SES and 
COPD prevalence, often showing .1.5 to three-fold greater 
in disadvantaged people; this holds true whether income or 
educational levels are used to define SES. The prevalence 
of emphysema, because it is more common in smokers than 
those exposed to BF, may exhibit a different relationship to 
SES depending on the country.61 The BOLD and PLATINO 
studies have been the most extensive studies of COPD 
internationally – both support the relationship between 
poverty and higher COPD prevalence.60,62
In most countries, people of low SES account for the 
majority of all COPD patients. In the US, although low 
SES people constitute the minority of the overall population 
(,20%), they account for nearly two-thirds of all patients 
with COPD63,64 or AO.22 Similarly, in a study of the Chinese 
population, people with low educational level accounted for 
43% of the survey population in rural areas but 81% of those 
were with COPD.65 Finish33 and Korean40 studies reported 
that two-thirds of subjects with COPD were in the lowest 
SES group based on education.
Risk factors for COPD in the lower 
SES population
Tobacco use
Long-term tobacco use is the most common cause of COPD 
in developed countries – this is most evident in people with 
low SES due to relatively high rates of tobacco use. In the 
US, where overall current use of tobacco is ,20% of adults, 
rates of current smoking are three- to fivefold higher in those 
with less than a high school education compared with col-
lege graduates.66 One of the authors of this article undertook 
a quality improvement project in four indigent medical 
clinics and found that current smoking rates were .70% 
among adult patients (R Pleasants, Duke Asthma, Allergy, 
and Airways Center, Duke University School of Medicine, 
personal communication, June, 2013). Often, these exposures 
begin early in life, as children in low SES settings are more 
likely to be exposed to environmental tobacco smoke from 
household members and these same people are more likely 
to eventually smoke tobacco products.
Some epidemiologic studies (for example, Twyman 
et al67) have shown that low education is associated with 
Table 2 Relationship between socioeconomic status and respiratory measures
References Population (description  
and N)
Socioeconomic status 
measure(s)
Outcome measure(s) Main findings
Trinder  
et al17
General practices in UK 
(N=4,237)
Occupation of 
householder
Respiratory symptoms Severity of respiratory symptoms worse 
in people with manual occupation in the 
presence of tobacco use
Shohami  
et al18
Adults in UK attending general 
medical practices (N=22,675)
Occupation, education 
level, and area deprivation
Lung function impairment Occupation, educational level, and living 
in area of deprivation associated with 
worse lung function
welle  
et al19 
Norwegian general population 
survey (N=1,275)
educational level DLCO DLCO related to education in men, not 
women
Schikowski 
et al20
Germany (N=1,251, women only) Education level, 
occupation, and residence
Lung function, 
respiratory symptoms, 
and air particulate matter
Low education more likely to suffer 
from low Fev1 and were occupationally 
exposed to particulate matter .10 ppm
Smith  
et al21
Chinese population (never 
smokers) in ten regions 
(N=307,000)
Household income and 
education level
Prevalence of AO AO associated with lower education 
and income
Kurmi  
et al22
Cross-section of adults in ten 
diverse populations across China 
(N=500,000 adults)
Household annual income Prevalence of AO and 
respiratory symptoms
AO inversely related to annual income
Liu et al23 Cross-sectional survey in one 
US state (N=4,300 adults)
education level Prevalence of respiratory 
symptoms
Low educational level associated 
with higher frequency of respiratory 
symptoms, including frequent 
productive cough, dyspnea, and SOB 
affects ADLs
Abbreviations: ADLs, activities of daily life; AO, airflow obstruction; DLCO, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; 
ppm, parts per million; SOB, shortness of breath.
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Table 3 Relationship between socioeconomic status and COPD prevalence 
References Population, description, 
and N
Socioeconomic 
status measure(s)
Outcome measure(s) Main findings
Bakke et al24 Cross-sectional study of general 
adult population in Norway 
(N=1,512)
Occupation Asthma and COPD 
prevalence
OR of 3.6 for obstructive lung disease 
in people with high degree of airborne 
exposure
Eachus et al25 Adults from 40 general practices 
in the UK (N=28,080)
Deprivation score 
based on residence
Disease prevalence 
including COPD
Emphysema and chronic bronchitis 
relative index of 2.72 and 2.27, 
respectively (values higher than most 
other conditions)
Chen et al26 National population survey in 
Canada (N=7,210)
Income COPD disease 
prevalence
For low income persons OR =3.7 for 
males and 2.4 for females
Marmot et al27 Civil servants in London, UK 
(N=10,308)
Occupation 
(employment grade)
Chronic bronchitis 
prevalence
OR for CB for men 1.44 and women 
1.21
Montnemery  
et al28
Adults in Sweden (N=12,071) Occupation, social 
position, and 
residence location
Prevalence of CBE and 
respiratory symptoms
CBE more common in unskilled 
and semiskilled workers, low social 
position
Lindberg et al29 Sweden (N=1,165) Occupation COPD incidence over 
10 years in subjects with 
respiratory symptoms
Manual workers had an OR =1.78 vs 
professionals. Low education level had 
an OR =1.73
Ellison-Loschmann 
et al30
european Community 
respiratory health Survey in 
Europe, Australia, New Zealand, 
and the US
educational level and 
occupational class
Prevalence and 
incidence of chronic 
bronchitis
Low educational and occupational 
levels (prevalence ratio =1.9 and 1.8, 
respectively)
Halvorsen and 
Matrinussen32
Norwegian prescription 
database of COPD patients 
(N=62,882)
educational level and 
level of unemployment 
in community
COPD prevalence Communities with low educational 
levels and unemployment associated 
with higher risk of COPD
Karnevisto et al33 Finland – national population-
wide survey (N=6,525)
education and 
household income
COPD and asthma 
prevalence
Education significant risk factor for 
COPD, whereas low household income 
was a risk factor for asthma
Lovasi et al34 Multi-ethnic study of arthero-
sclerosis at multiple sites in 
the US (N=3,706)
Education, household 
income, and wealth 
indicators
Degree of emphysema 
on computed 
tomography scan
Higher percent of emphysema in people 
with lower high school education, 
annual income, and wealth
Yin et al35 People’s Republic of China 
(31 provinces), (N=49,363)
education and 
household income
COPD prevalence by 
self-report
SeS predictive of COPD risk 
independent of smoking and rural vs 
urban residence
Herrick et al36 Cross-sectional population 
study in one US state 
(N=25,986)
Annual household 
income and highest 
level of education
COPD prevalence COPD prevalence threefold greater 
between highest and lowest income 
levels as well as between lowest and 
highest education levels
Burney et al60 Multicenter (n=22 countries), 
international study burden 
of obstructive lung disease 
(N=15,355)
Poverty as measured 
by GNI of countries
COPD prevalence COPD prevalence fivefold greater 
between highest and lowest income 
levels as well as between lowest and 
highest education levels
Kainu et al37 Finnish population (N=8,000, 
COPD N=628)
Occupation COPD prevalence Prevalence higher in manual than 
nonmanual occupations
Golec et al38 Polish farmers (N=64) Size of farm COPD prevalence Lower SeS in COPD patients
Hagstad et al39 Swedish never-smokers with 
obstructive lung disease 
(N=967)
Education level, 
occupation
Proportion of 
nonsmokers with 
COPD who had 
occupational exposures
OR of COPD related to 
occupation =0.72 in college graduates 
vs those with less than high-school 
education 
Lee et al40 Korean never smokers with 
COPD (N=3,473)
Educational level, 
occupation
COPD prevalence Low education level and manual labor 
were risk factors for COPD
Tan et al41 Canadian cross-sectional study 
in general adult population 
(N=5,176)
educational level COPD prevalence in 
ever and never-smokers
Low education level associated with 
higher prevalence in both never and 
ever-smokers
Abbreviations: CB, chronic bronchitis; CBE, chronic bronchitis/emphysema; COPD, chronic obstructive pulmonary disease; GNI, gross national income; OR, odds ratio; 
SES, socioeconomic status.
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Table 4 Effect of socioeconomic status on respiratory-related outcomes in chronic obstructive pulmonary disease
References Population SES measure Outcome measure(s) Main findings
Prescott et al43 Copenhagen, Denmark 
general population 
(N=14,223)
educational level and 
household income
Hospitalization for COPD Higher rates of hospitalization 
related to income and education 
levels (independent of smoking 
history)
van Rossum et al42 the Netherlands 
(N=18,001)
Occupation Mortality COPD had highest rate of 
increased mortality related to 
occupation compared with other 
common causes of death
Steenland et al11 Adults in 27 states in the 
US, American Cancer 
Society population 
(N=1,330,886)
Occupation All cause and cause-specific 
mortality
SES gradient most substantial for 
all specific causes of death
Huisman et al44 european data from 
numerous countries 
(N=1,000,000 deaths)
education level Mortality rate in low-
educational groups expressed 
as a proportion of mortality 
rate in high-educational groups 
Low education groups had highest 
mortality including COPD, cancer, 
and heart disease
Antonelli-Incazi 
et al45
Elderly in Rome, Italy Income based upon 
census tract estimate for 
residence
Hospitalization rate of COPD Relative risk for females with 
COPD 3.3 and males 4.3 (higher 
than other diseases)
Blanc et al46 US population survey of 
COPD patients (N=427)
educational level and 
annual income
Tiotropium use Less use of tiotropium with lower 
SeS (OR =0.3)
Reilly et al47 National survey of 30 
provinces in the People’s 
Republic of China 
(N=169,871)
Education, residence 
(urban vs rural)
Mortality Relative risk of death 2.37 
and 2.47 for men and women, 
respectively. RR for urban vs 
rural residence 2.14 and 1.79, 
respectively
Schane et al48 National cross-sectional 
US survey (N=18,858 
total N=1,736 COPD 
patients)
Income and education Risk factors for depression in 
COPD vs non-COPD
Less than HS education showed 
OR =1.63 for depression
Wong et al49 Data from St Paul’s 
Hospital in Vancouver, 
BC, Canada
Marital status and need for 
social work consultation 
while in hospital
Hospital LOS and readmission 
rate in AeCOPD patients
Marital status and need for social 
work intervention associated with 
prolonged LOS and readmission 
for AeCOPD
Lewis et al10 National Longitudinal 
Mortality Study in the US 
(N=184,924)
Marital status, education, 
health insurance, poverty 
level, and occupation
Mortality in a general adult 
population
Education, marital status, and 
income predictive of mortality, not 
seen with insured vs uninsured
Arne et al50 Sweden, survey of 55 
municipalities (N=1,475)
Education level, 
employment status, and 
social support
Health status and quality of 
life in COPD vs non-COPD 
subjects
Lack of social support and low 
economic status associated with 
poorer health status in COPD 
Calderón-Larrañaga 
et al51
UK, national cross-
sectional study 
(N=53,676,021)
Deprivation index Hospitalizations for COPD Deprivation and smoking 
prevalence were variables with 
highest explanatory power, 
accounting for 59.3% and 51.4%  
of the total variance, respectively
Miravitlles et al52 Spain, nationwide survey 
(N=4,574)
education level and 
occupation
HrQOL in COPD patients Worse HrQOL in low education 
level and in unskilled workers
eisner et al31 CA, in the US (N=1,202) 
(insured COPD patients)
education and income 
levels
Physical impairment (6-minute 
walk), pulmonary function, 
and disease severity including 
BODE index
Low SES associated with worse 
physical impairment, pulmonary, 
function, and disease severity in 
a COPD population with broad 
access to health care
Omachi et al53 CA, in the US, population 
survey in persons 
.55 years (N=277)
Health literacy COPD-related health status 
and COPD-related ED 
or hospitalizations using 
multifactorial analysis adjusted 
for income and educational levels
Poorer health literacy associated 
with worse health status, HrQOL, 
and ED and hospitalizations for 
COPD
(Continued)
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lower odds of quitting tobacco compared with persons of 
higher educational attainment. Some hypotheses include 
1) impoverished people are less likely to seek treatment for 
tobacco addiction because of significant life stressors, 2) 
smoking is often socially accepted among their family and 
peers, 3) they have lower levels of knowledge of benefits 
of smoking cessation drug therapies, 4) health care provid-
ers believe that this population is less interested in quitting 
smoking, 5) they have higher rates of mental health issues 
including multisubstance abuse, and 6) genetics. Though 
these are hypothesized explanations for the disparity in 
smoking cessation rates in low SES groups, there are no 
randomized controlled data to support a causal relationship. 
In addition, many epidemiologic studies often leave out key 
variables in their analysis. One study found that smoking 
behaviors including age of initiation, intensity of tobacco 
use, and smoking cessation capabilities appear to be geneti-
cally related.68 In the COPD Gene trial, it was found that 
in a genetic analysis of .3,000 COPD patients, the age of 
onset of tobacco use and smoking cessation behavior were 
related to nicotinic receptors and hepatic metabolism of 
nicotine.4 Neither study examined the relationship of genet-
ics, smoking, and SES.
However, in less-developed countries with very wide 
social gradients, the poorest are unable to afford tobacco 
products, and therefore, long-term tobacco use is less likely 
to be the leading cause of COPD. In Peru where tobacco 
use is very low in the adult population (3.3%), smoking 
accounts for ,10% of all COPD cases. COPD was more 
likely to be due to posttuberculosis infection and indoor 
BF; the latter accounting for 60% of the COPD cases.69 In 
some countries such as Uganda, some of the poor grow 
their own tobacco and therefore have ready access to 
tobacco.
Occupation
In the US, it is estimated that ~15% of COPD cases could 
be attributed to inhaled particles at work such as production 
of plastics, textiles and leather, building and construction, 
military service, food, crops, chemicals, petroleum, and coal 
mines.70 Disadvantaged people tend to be the ones working 
in these environments. However, occupation-related COPD 
often does not occur in isolation, as many at-risk people have 
exposures to harmful particles in the household and outdoor 
environments. A greater risk of COPD has been reported with 
combined occupational and smoking exposures. The odds 
ratios ranged from 4.0 to 6.2 for COPD among occupationally 
exposed smokers, compared with 1.4–3.2 for occupationally 
exposed never-smokers.71,72 In another study, the difference 
between occupationally exposed never-smokers and occu-
pationally exposed ever-smokers was reported to be even 
greater (14-fold).73
Table 4 (Continued)
References Population SES measure Outcome measure(s) Main findings
McAllister et al54 All Scottish residents (UK) Scottish Index of Multiple 
Deprivation (measure 
using multiple domains 
such as income, housing, 
access, education)
Hospitalization rates in COPD 
associated with deprivation 
index and winter season
SES and winter act synergistically 
on rate of COPD hospitalizations
Gershon et al55 ON, Canada Average household 
income based on 
residence
Mortality of COPD Although overall COPD mortality 
decreased between 1966 and 2012, 
differences in COPD mortality 
between low and high income 
widened over the study period 
Lange et al56 Copenhagen, Denmark 
(N=6,590) adults with 
COPD
education ,8 years,  
8–10 years, .10 years 
with some college or 
completed college
AECOPD, hospital admissions, 
mortality
Highest risk of AECOPD, 
low lung function, and highest 
respiratory symptoms
Trachtenberg  
et al57
Administrative database 
in Winnipeg, Canada 
N=34,741 asthma and 
COPD)
Census-based household 
income
Hospitalizations for asthma or 
COPD
Lower SES associated with higher 
risk of hospitalizations
Sharma et al58 US Medicare beneficiaries 
with COPD 
Socioeconomic status 
based on if Medicaid 
eligible (low SES)
Burn injuries related to 
oxygen use
Twofold risk of oxygen-related 
burn injuries in low SeS people
Abbreviations: AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; ED, emergency department; HrQOL, health-related quality of life; 
LOS, length of stay; OR, odds ratio; RR, relative risk; SES, socioeconomic status.
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In a National Health and Nutrition Examination Survey 
study in the US, occupations associated with an increased 
risk of COPD were freight, stock, material handlers, records 
processing and distribution clerks, sales, transportation-
related occupations, machine operators, construction trades, 
and waitresses.74 The fraction of COPD attributable to work 
was estimated as 19.2% overall and 31.1% among never 
smokers. The majority of workers in high-risk occupations 
had low income and education levels. In a more recent Swiss 
study of working adults, occupational exposures to biological 
dusts, mineral dusts, and gases/fumes were associated with 
two- to fivefold higher incidence of COPD of at least mod-
erate severity; however, SES measures were not reported.75
Household and outdoor pollution
Almost 3 billion of the world’s poorest rely upon solid 
fuels (wood, animal dung, charcoal, crop wastes, and coal) 
burned in inefficient, polluting stoves for cooking, lighting, 
and heating – leading to premature deaths from respira-
tory and cardiovascular diseases and cancer.76 It has been 
suggested that BF is a more common cause of COPD than 
cigarette smoke globally.77 The use of gas stove and solid 
fuels for cooking, lighting, and heating78,79 and air pollu-
tion have been linked to increased respiratory symptoms, 
impaired lung function,80–82 and development of COPD.83,84 
Although the role of air pollution in causing COPD is not 
clear, high levels of outdoor pollution are an important 
contributor to an increased risk of acute exacerbations of 
COPD85 and possibly mortality.86
Much of the combustible fuel exposure is related to poor 
housing conditions such as overcrowding and poor ventila-
tion when using BF. In addition to consistently conferring 
a higher risk of the emergence of COPD, it also increases 
the risk of acute respiratory infections.87 Women appear to 
be particularly at risk to develop biomass-related COPD, 
although environmental tobacco smoke may play a role.80 
Meta-analyses have reported approximately twofold greater 
odds of developing COPD in people exposed to BF.84,88
In a cohort study in the US, use of wood for indoor heat-
ing in fireplaces or woodstoves increases the risk of COPD 
among current smokers, Caucasians, and men.89 These effects 
remained even when controlling for age, smoking, and 
educational level. Wood smoke may lead to greater risk of 
developing COPD,90 whereas indoor use of coal for heating 
may be more likely to increase the risk of lung cancer.91
Outdoor air pollution is also an important factor that 
causes lung diseases in people of low SES as they tend to 
live in poor housing, less desirable areas in close proximity 
to highways, and pollution-producing manufacturers and are 
therefore exposed to disproportionate amounts of inhalant 
toxins. In the US, the estimated proportion of the population 
living near a major highway was 4.2% for the poor, 3.7% 
for the near-poor, and 3.5% for the nonpoor categories.92 
In a longitudinal study of 4,757 women in Germany, it 
was found that chronic exposure to PM
10
 and nitric dioxide 
and living near a major highway led to an increased risk of 
COPD (1.8-fold).20
Intrauterine and childhood exposures
Exposures, beginning with the fetus continuing throughout 
childhood, can have an impact on the trajectory of lung 
function development and ultimately long-term respiratory 
health. Intrauterine exposure to tobacco as well as second-
hand smoke in young people are important risk factors for 
developing both asthma and COPD, especially in disad-
vantaged people.93–99 In the US, smoking rates in women 
during the 3 months prior to pregnancy are similar to the 
general population (~20%), decline to ~10% of women 
while pregnant, and then increase close to pre-pregnancy 
rates postpartum.100 Women of low SES tend to smoke more 
during and after pregnancy. In a UK study, women of low 
SES were three times more likely to smoke during pregnancy 
than higher SES women.101 One study found a positive asso-
ciation between fetal size at 10 weeks gestation and FEV
1
 
in 10-year olds.95 Another study found that smoking during 
pregnancy, particularly in first trimester, is associated with 
worse respiratory complications in children.102
Lung function impairment and respiratory symptoms after 
birth and through childhood are also associated with asthma 
occurrence in later years,95–97 ultimately increasing the risk 
of developing COPD later in life.100,103 In children, chronic 
exposure to air pollution is associated with a reduction in age-
related forced vital capacity and lung growth.104 However, 
other studies found that there was no effect or inconclusive 
evidence for longitudinal changes in lung function.94,105,106 
A Swedish study of 2,278 children looked at the effect of 
air quality during the first year of life on lung function at 
16 years of age.93 Early life exposures to traffic-related air 
pollution during the first year of life resulted in lower FEV
1
, 
especially in males. Biomass smoke is also an independent 
risk factor for COPD in people exposed in early life.84 Lastly, 
impaired lung function in early adulthood is also associated 
with an increased risk of developing COPD.107
It is also known that recurrent childhood respiratory 
tract infections can lead to the development of lung dis-
eases later in life108–111 and that low SES increases the risk 
of childhood respiratory tract infections. In one study early 
childhood respiratory infections as well as a history of 
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asthma in the family were significant determinants of COPD 
risk.110 A recent 50-year longitudinal study of a cohort of 
children beginning at 10–15 years of age found that asthma 
and wheezy bronchitis associated with viral infections led 
to increased risk of developing COPD, while considering 
smoking history.111
Health care access
Disparities in health care access persist despite efforts for 
many years to improve care for underserved patients, ethnic 
and racial minorities, and the underinsured. Access to health 
care providers, diagnostic testing, and medications are often 
more limited in disadvantaged people, although universal 
health insurance in some countries lessen health disparities. 
In addition to access being an issue in the low SES people, 
lower literacy levels also impact their health status and 
other outcomes.53
Shortage of primary care and specialist physicians in some 
communities is an important factor for the unequal provision 
of health care quality and access to health care services.112,113 
In the US, Spain, and many developing countries, relatively 
few pulmonologists and specialty services such as spirometry 
and pulmonary rehabilitation are available to disadvantaged 
people.8 In the US, minority patients with asthma are less 
likely to be referred to specialists than whites.114
Access to health care is not the only important factor in 
health disparities; the Black Report emphasized that despite 
free health care provision through the National Health 
Service, health disparities in mortality rates by social class 
were evident.115 A US study showed that in people provided 
with similar health insurance, those with low SES had worse 
health outcomes than those at with high SES.31 In contrast, a 
Canadian study found that there was no difference in COPD 
mortality between people of low and high education – this 
was felt to be due to universal health coverage and the greater 
acute health care utilization by low SES people.116 Therefore, 
it is not just a matter of providing health care resources at 
a low cost to people of low SES, but it must involve other 
additional strategies to promote healthy behaviors in these 
patients and other contributors that affect health outcomes.
Disparities also exist in tobacco cessation advice 
from health care providers.117,118 In a US study, compared 
to Caucasian smokers, African–American and Hispanic 
smokers were approximately two-thirds less likely to be 
asked by their doctor about tobacco use and not have used a 
cessation medication. These differences were unexplained 
even when factors known to impact these rates were consid-
ered.117 In another study, low SES people were less likely 
to receive provider-assisted assistance in stopping smoking 
than higher SES people.118 New quality outcome measures 
requiring screening for tobacco use by health care providers 
in the US have decreased this disparity.
Affordability and access to effective COPD medications is 
a major barrier in many disadvantaged people. In some impov-
erished countries, the national formularies have very limited 
choices for the treatment of COPD. One US study showed 
that low SES people were only one-third as likely to have 
used their inhaled tiotropium.46 An important problem with 
COPD medication costs is the lack of availability of cheap 
generics; in part because regulatory agencies, such as the US 
Food and Drug Administration, have higher expectations for 
inhaled generic equivalents than for oral generics.119
Clinical characteristics of COPD in 
people of low SES
Both biomass and tobacco smoke are generated from the com-
bustion of plant materials, which produce complex carbon-
based particles and organic compounds such as hydrocarbons 
and irritant gases. Biomass smoke increases the expression of 
some matrix metalloproteinases similar to tobacco smoke.120,121 
Like tobacco smoke, BF leads to chronic inflammation, 
increased oxidative stress, and respiratory symptoms.122 
Combined exposures to tobacco smoke and BF have additive 
effects on the risk of developing lung diseases.90
Clinical features tend to differ between tobacco smokers 
and people exposed to BF.61,123–126 In a study of women with 
severe COPD, comparing wood smoke-related and tobacco 
smoke-related COPD, there were no significant differences 
between the two groups in terms of AO, resistance, or hyperin-
flation. However, bronchial hyper-reactivity was more evident 
in the former.123 In another study, those exposed to BF scored 
lower on the symptom and activity scores using a quality of 
life assessment.61 This study also showed that women in the 
biomass group had significantly more air trapping than the 
tobacco group (radiologist score was 2.6 and 1.5, respectively) 
and had lower oxygen saturation at rest and during exercise. 
In another study in Columbia, South American women with 
chronic bronchitis secondary to long-term wood smoke 
inhalation, dyspnea, AO, air trapping, and increased airway 
resistance were common.125 Additional research is needed 
in this area as tobacco smoking becomes less prevalent and 
other causes of COPD become more common.
Several studies have examined the radiologic and patho-
logic characteristics of biomass vs tobacco smoke-related 
COPD.34,61,125–127 One study, using 3,706 multiethnic subjects 
enrolled from six distinct US locations (Multi-Ethnic Study 
of Atherosclerosis), examined the relationship among SES, 
emphysema scores, and other measures.34 One-half of the 
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subjects were current or former smokers, one-third had 
occupational dust exposure histories, and one-third were born 
outside the US. Those who did not complete high school had 
more AO than those with a graduate degree, whereas, unex-
pectedly, the less well-educated people had a lesser extent 
of emphysema. However, to what extent biomass exposures 
contributed to this discrepancy was unclear. In a study of 
43 Mexican women, grouped by tobacco smoking or BF 
exposure, computed tomography (CT) scans showed that the 
tobacco group had significantly more emphysema than the 
biomass group (radiologist score was 2.3 vs 0.7; emphysema 
on CT 27% vs 19%, and a larger size of emphysematous 
spaces).61 In another study of Mexican women with COPD 
secondary to wood smoke inhalation (n=12) vs smoking-
related COPD (n=10), pathological evidences of anthracosis, 
chronic bronchitis, centrilobular emphysema, and pulmonary 
hypertension were present in most patients exposed to wood 
smoke.125 In an autopsy study of 48 Mexican COPD patients, 
emphysema was less likely to be severe in BF patients than 
in smokers.127 Small airways fibrosis was more evident with 
BF, whereas increased goblet cell hyperplasia and emphy-
sema were seen in smokers. Emphysema was more evident 
in the smokers. In terms of survival, a 7-year follow-up study 
showed that women with biomass-induced COPD have simi-
lar survival rates as men with tobacco-related COPD.124
Effect of SES on COPD outcomes
Table 4 lists the studies that show a strong association 
between low SES and worse outcomes in COPD patients 
including death, emergency department (ED) visits, hos-
pitalizations, medication use, and health-related quality of 
life.11,43,44,54–56,60,128 There may be sex differences as one study 
reported that occupation and education were predictors of 
death in men, whereas only education was significant in 
women.43 In a systematic review, among several common 
causes of death (COPD, diabetes, heart disease, all can-
cers, and stroke), the relationship with SES was strongest 
for COPD-related deaths.55 However, with regard to lung 
cancer (vs all cancers), the association between SES and 
risk was also quite strong,128 therefore how various causes 
of death are categorized may affect the reported association 
between mortality and SES. A BOLD study analysis found 
that smoking is the most important cause of AO, but air-
flow restriction was more associated with mortality in poor 
countries.60 With regard to COPD mortality, people in lower 
SES groups comprise between one-half to three-fourths of all 
deaths where COPD is reported to be the primary cause.10,11,129 
A recent Canadian study showed that the mortality gradient 
between low and high SES is slowly widening (Figure 1).55 In 
countries where current smoking rates continue to decline in 
higher SES groups such as the US and Canada, although rates 
Figure 1 All-cause mortality rate by socioeconomic status among COPD patients in Canada from 1996/1997 to 2011/2012.
Note: Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. Gershon AS, Hwee J, Victor JC, Wilton AS, To T. 2014. 
Trends in socioeconomic status-related differences in mortality among people with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 11:1195–1202. The Annals of 
the American Thoracic Society is an official journal of the American Thoracic Society.55
Abbreviation: COPD, chronic obstructive pulmonary disease.
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decline more slowly in disadvantaged people, this gradient 
will likely widen even further. However, the impact of SES on 
mortality is not seen with all COPD patient types. A UK study 
found that mortality in alpha-1 antitrypsin patients was no 
different as a function of educational status or occupation,130 
likely because it is a genetically driven cause of COPD.
Other outcome measures that are affected by SES in COPD 
patients are health-related quality of life,52 depression,48 
medication (tiotropium and albuterol) use, ED visits, 
hospitalizations, and burn injuries from home supplemental 
oxygen.58 These disparities existed even in people who have 
ready access to health care.10,31 Hospital readmission for acute 
exacerbation of COPD (AECOPD), now a quality measure 
in the US hospitals, is also more common in disadvantaged 
COPD patients.49 A UK study, examining the relationship 
between air pollution and albuterol prescriptions by primary 
care physicians, found that deprivation was associated with 
greater prescribing.131 Conversely, maintenance therapy use 
is decreased in low SES people.46
Strategies to aid the diagnosis and 
management of COPD patients 
with low SES
There is an old adage in the US supposedly quoted from a 
famous bank robber named Willie Sutton that evolved into 
Sutton’s law used in clinical medicine. Sutton reputedly 
replied to a reporter’s inquiry why he robbed banks that 
“because that’s where the money is”.132 Translated into where 
the greatest opportunities and challenges exist for COPD, it 
is targeting low SES populations and that is where the money 
and other resources need to be directed.
In reality, to make substantive changes in COPD risk fac-
tors and social determinants of health, health equity strategies 
must be part of larger, multifaceted efforts that will always 
depend on societal changes that can be very difficult to 
achieve. Broadly speaking, there are three important principles 
that should be included in the strategies to improve COPD 
health equity: 1) include all stakeholders in the development 
and implementation of interventions; 2) adapt interventions 
to address the unique barriers and facilitators of the disparate 
population; and 3) create implementation strategies target-
ing all levels of the socioecologic framework – individual, 
interpersonal, organizational, community, and public policy. 
Stakeholders can vary from government agencies, health 
care organizations such as WHO, ATS, ERS, health insurers, 
health care institutions, research organizations, health care 
providers, patients, and community groups. The remainder 
of this section focusses approaches that may be applied by 
individuals or in local settings.
Some strategies that might be employed include 1) priori-
tize population screening and case-finding in people of low 
SES to identify symptomatic people with exposure histories in 
this high-risk population; 2) undertake educational efforts in 
people with low SES using culturally sensitive strategies 
in local communities; optimally beginning at a young age 
regarding the use of tobacco products, indoor biomass, 
second-hand smoke, and COPD; 3) provide alternatives to 
the use of indoor biomass cooking; 4) identify cost-effective 
strategies for health care in this population; and 5) identify 
existing and potential strategies to save medication costs and 
optimize adherence.
Organizational strategies
The WHO, ATS, ERS, Forum of International Respira-
tory Societies, and European COPD Coalition are among 
the health care organizations that are responding to the 
problems surrounding COPD and SES. Some key ATS 
efforts targeting health disparities include establishing a 
group called the Lung Corp,133 publishing a perspective of 
respiratory health equality in the US,134 and a joint policy 
statement with ERS on disparities in respiratory health.8 The 
ATS created the Lung Corps to reduce health disparities 
through the promotion of research, training, disseminating 
best practices and monitoring, and advocating lung health 
to the public. In addition, an ATS subcommittee reported 
that attainment of respiratory health equality necessitates the 
end of disparities, which would require a multidisciplinary 
effort targeting environmental exposures, encouraging 
healthy lifestyles, and optimizing the prevention, screen-
ing, diagnosis, and management of lung diseases.136 A joint 
ATS/ERS policy statement8 describes actions including 
developing educational programs for health care providers 
and policy makers to reduce disparities, holding confer-
ences addressing health care disparities, and collaborating 
with other organizations such as the WHO. ATS/ERS 
jointly plans to decrease disparities by 1) guiding research 
agendas, 2) increasing healthcare provider awareness of 
disparities, 3) advocating for appropriate policies, and 4) 
tracking progress with disparities. Nearly 2 decades ago, 
ATS developed the Methods in Clinical and Operational 
Research program to increase the numbers of public health, 
academic, and clinical leaders to facilitate research and its 
application in public health and health care to respiratory 
diseases in various countries. The recent ATS/ERS research 
priorities publication did not address health disparities as 
one of the research priorities, but did state that the natural 
history of the disease should be studied with regard to race, 
sex, and SES.135
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The Forum of International Respiratory Societies 
developed a guide on preventing and treating lung diseases, 
including COPD.136 Principal recommendations include 
increase public awareness, target environment and tobacco, 
increase public health and clinical research, and train more 
health care providers globally to deal with lung diseases. 
It also recommended developing cost-effective management 
protocols for COPD in low-income settings. The European 
COPD Coalition has published a call for action among 
countries in the European Union to better target COPD.137 
Among multiple recommendations, it was stated that the 
European Union should support and initiate research on 
social and environmental determinants of health to bet-
ter understand factors that increase the risk of developing 
COPD in Europe.
The WHO has a number of publications addressing COPD 
and SES including an essential medicine list, tobacco pre-
vention strategies, guidelines to reduce indoor BF exposure, 
prevention of chronic respiratory tract diseases, and managing 
COPD in low SES settings.138–143 WHO recommenda tions for 
the diagnosis and management of COPD in low SES settings 
by primary care providers have been published.142 Consider-
ing the lack of availability of spirometry in many low-income 
settings, WHO recommends the use of clinical history and 
peak expiratory flow measurement to guide the diagnosis 
of COPD. Severity of COPD is judged based on symptoms. 
Education of the patient and family is recommended regard-
ing biomass fuels, occupational exposures, and tobacco 
smoke. Recommended drug therapies included short-acting 
β2-agonists and low dose oral theophylline. They also state 
that ipratropium may be an option, but may be too expen-
sive.142 Regarding tobacco, WHO embraces the MPOWER 
acronym approach for tobacco: Monitor tobacco use and 
prevention policies, Protect people from tobacco smoke, 
Offer help to quit tobacco use, Warn about the dangers of 
tobacco, Enforce bans on tobacco advertising, promotion, 
and sponsorship, and lastly Raise taxes on tobacco.139 Goals 
of the WHO Strategy for Prevention and Control of Chronic 
Respiratory Diseases are to improve 1) surveillance to map 
and analyze the determinants with particular reference to 
poor and disadvantaged populations and to monitor the future 
trends, 2) primary prevention to reduce the level of exposure 
of individuals and populations, and 3) secondary and tertiary 
prevention to strengthen health care for people with chronic 
respiratory diseases.141 WHO also provides a list of essential 
medicines for many diseases that is updated every 2 years.138 
Additionally, the WHO has begun a noncommunicable 
chronic diseases monitoring system for .190 countries.143
Surveillance
Opportunities for surveillance include expanding epide-
miologic studies in more low SES settings and using these 
data to aid efforts such as to screen for undiagnosed disease. 
Despite the tremendous global burden of chronic respiratory 
disease, there are relatively limited data on its prevalence, 
natural history, and associated morbidity and mortality of 
COPD in LMICs.144 However, there has been significant 
progress in defining the prevalence and impact of COPD 
globally through surveillance studies – particularly with 
the newer BOLD and PLATINO international studies, 
additional studies in Africa,145 and in the US with the expan-
sion of the Behavioral Risk Factor Surveillance System for 
COPD prevalence.146,147
Ideally, each surveillance system should be capable of 
describing disease prevalence and disease impact in disparate 
people as well as the overall population. Furthermore, the 
information must be communicated to appropriate people 
including policy makers, health care providers, and the popu-
lation from which the data were derived. This is largely a 
role of the public health sector in collaboration with others 
involved in health care provision. In general, the lay public’s 
knowledge of COPD is far less than that of other diseases 
such as asthma, cancer, and heart diseases;148,149 therefore, 
it is imperative to educate the general public about COPD, 
partially relying on these surveillance data. Ideally, this 
education should occur throughout the population including 
the educational systems of young people.
One proposed strategy is to provide annual reports on 
lung health surveillance data from vulnerable, disparate 
populations.150 The WHO has recently begun a multinational 
surveillance of chronic diseases to better monitor low SES 
populations.143 In the US, a Nationwide Framework for 
Surveillance of Cardiovascular and Chronic Lung Diseases 
recommends to provide such data through surveillance 
to analyze disparities in disease prevalence, risk factors, 
outcomes, and health care delivery. It was recommended to 
integrate various surveillance systems into a central system 
that is able to function nationally and locally.151 In addition 
to the use of the Behavioral Risk Factor Surveillance Sys-
tem health survey, the US Centers for Disease Control and 
Prevention also recently expanded surveillance for COPD 
through the use of chronic disease indicators.152 The chronic 
disease indicators are used by epidemiologists at local, state, 
and national levels in the US to monitor many major chronic 
diseases. The updated indicators are 1) mortality of COPD as 
a primary or secondary cause, 2) COPD prevalence, 3) ED 
visits with COPD as a primary or secondary cause, and 4) 
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hospitalizations as a primary or secondary cause. Previously, 
only mortality was included in these measures; inclusion of 
COPD as comorbidity in surveillance of other diseases will 
provide greater perspective of its impact across health care.
Primary prevention
Of all possible interventions, primary prevention for COPD 
through the avoidance of exposure to inhalant toxins would 
have the most impact on this disease; however, this is dif-
ficult to achieve in disadvantaged people. Both strategies and 
interventions are necessary to target low SES communities 
by improving housing conditions, providing education on 
tobacco in people at a young age, reducing tobacco use, and 
reducing other detrimental environment exposures, however, 
interventions are not often implemented.
To have an impact on tobacco use in the low SES popu-
lation, it will require societal changes and efforts by health 
care organizations, public health, and individual providers. 
Societal interventions that can impact tobacco use include 
raising taxes on cigarettes, banning the use of tobacco 
in certain settings such as health care facilities, schools, 
government facilities, restaurants, and bars, and restrict-
ing advertisement.100 A study conducted in one US state 
showed that communities with smoke-free public policies 
had significantly lower rates of COPD hospitalizations.153 
A recent Cochrane Review reported that national smoking 
bans in 21 countries led to improvement in multiple outcome 
measures.154 Because people who are more educated smoke 
tobacco at much lower rates, it is logical that improving 
secondary and tertiary education programs for the low SES 
population would contribute significantly to lower smoking 
rates. Education access and performance are heavily deter-
mined by family background, including family income and 
environment, which can strongly influence cognitive and 
noncognitive abilities.
As a whole, health care providers perform suboptimally 
in assisting patients to quit smoking. A 2007 report by the 
American Association of Medical Colleges on physician 
behavior showed that most physicians consistently ask 
patients about their smoking status and advise them to stop 
(86%) if a smoker, but steps afterward were infrequent.155 
Physicians indicated the tools, training, and resources to aid 
patients effectively in stopping smoking are inadequate.
There are limited studies evaluating smoking cessa-
tion interventions in low-income people.156,157 One study 
used a systematic, telephone-based intervention involving 
counseling, nicotine replacement therapy, and commu-
nity resources, to double the quit rates (17% vs 8%).156 
Identifying and reaching out to poor people in their local 
communities was an important part of this program. In 
reality, typical interventions should be effective, but there 
is such a large number of smokers who are of low SES, and 
they are less inclined to quit, therefore the task is large. A 
national smoking cessation approach in Denmark was able 
to achieve reasonable abstinence rates in low SES people, 
however were still 30% lower in the low education vs the 
high education group.157
Perhaps idealistic, the best approach for a physician 
to effectively facilitate smoking cessation is as follows: 
1) ensure determination of smoking status, 2) the provider 
and other team members advise smoker to quit, 3) if the 
patient is willing, the prescriber initiates further steps with 
a simple prescriptive order, where drug therapy and coun-
seling resources are available and are provided directly to 
the patient thereafter, and 4) the provider sees the patient 
in follow-up. Unfortunately, there are multiple barriers 
inhibiting this optimistic model in many settings, much of 
it are resource based. Of note, the WHO essential medicine 
list includes nicotine replacement therapy. In the US, the 
cost of nicotine replacement therapy is comparable to the 
costs of smoking 20 cigarettes per day; therefore, cost of 
this therapy should be no different than that of smoking for 
most people.
Household air pollution is a modifiable exposure for 
which specific interventions such as the use of improved fuels 
(higher on the fuel ladder) for cook stoves, gas lighting, or 
heaters may be effective in lowering the risk of COPD.158 
The WHO provides guidelines for lowering indoor exposure 
to burning BF.140 Some of the key recommendations include 
1) exposure to fine particulate matter (PM 2.5) should not 
exceed 0.23 mg/min when unvented (eg, without a chimney 
or hood) and 0.80 mg/min when vented (eg, with a chimney 
or hood); 2) amount of carbon monoxide should not exceed 
0.16 g/min for unvented devices and 0.59 g/min for vented 
devices; 3) unprocessed coal should not be used as an indoor 
fuel; and 4) kerosene should not be used as an indoor fuel. 
The WHO recommends biogas, ethanol, liquefied petroleum 
gas, and natural gas as safer alternative fuels. In addition to 
cleaner fuels, vented, more efficient biomass stoves might 
also serve to decrease indoor exposure. There is an interna-
tional effort to bring safer BF in homes by the UN Foundation 
Global Alliance for Clean Cookstoves and the Climate and 
Clean Air Coalition.159 Unfortunately, the less expensive 
fuel options are generally less efficient fuels, produce more 
smoke, and are used by people with the most poorly designed 
homes. Cleaner fuels such as propane or liquid petroleum 
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gas burn very cleanly, but are often too expensive for many 
impoverished households.
A number of studies show that reducing BF exposures 
improves respiratory outcomes. In 2011, a randomized, 
controlled study (RESPIRE 6) showed that a reduction in 
disease activity is possible – in this case, there was a decrease 
in severe pneumonia in children after a chimney stove 
intervention to reduce indoor air pollution.160 Romieu et al 
conducted a trial in .500 Mexico women to evaluate the 
effect of a chimney wood stove intervention vs the traditional 
open fire stove on respiratory symptoms and lung function.161 
Although the adherence was poor (50%), use of the chimney 
stoves reduced respiratory symptoms (rate ratio of 0.29 for 
wheezing) and decline in lung function (31 vs 62 mL) over 
a 1-year period compared with those using open fire.161 In 
another study, investigators from the People’s Republic of 
China followed participants for up to 9 years and found that 
using biogas instead of biomass for cooking reduced the 
annual decline of FEV
1
 by 12 mL per year and improved 
kitchen ventilation reduced the decline by 13 mL per year, 
compared with those who took up neither intervention.162 One 
study in Columbia, South America, showed that conversion 
to natural gas heating led to a reduction in outpatient visits 
and hospitalizations for COPD.163 In the US, the Environmen-
tal Protection Agency has new recommendations on indoor 
wood stoves to decrease particulate emissions.164
Although ambient air pollution has well-documented 
the adverse effects on patients with COPD, the evidence for 
air pollution as a cause of COPD is inconclusive.87 A study 
before and during the 2008 Beijing Olympics showed that 
the risk of asthma outpatient visits declined with lower ozone 
levels that occurred with changes in automobile use and 
manufacturing preceding and during the games.165 Regard-
ing air pollution, minimizing exposure on poor air quality 
periods may aid in lessening the symptoms or preventing the 
exacerbations in COPD patients. Therefore, having daily, 
easily accessible air quality reports to the general population 
including people with lung disease is valuable, particularly 
for those with severe disease.
Prevention through appropriate immunizations can 
improve outcomes in the COPD population from influenza 
and pneumococcus infections.166 Pertussis can be associated 
with AECOPD,167 but there is no evidence that vaccination 
can decrease the risk of AECOPD. Like many other aspects 
of health care in low SES, immunizations are less likely to 
be administered appropriately in disadvantaged people in 
most,168,169 but not in all settings.170 Countries with fully funded 
immunization programs have higher rates of utilization.170
Health care access
Access to health care is a common barrier to good health 
in disadvantaged people because of the lack of resources 
and local availability of primary care and specialists. This 
is particularly true in rural areas, where a significant seg-
ment of the COPD population resides. Too often, care for 
disadvantaged people occurs in EDs, where care is very 
costly and not optimal as the principal site of health care for 
COPD patients. In the UK, a survey showed that the majority 
of patient contact with health services occurs via either the 
general practitioner or an emergency admission to hospi-
tal.171 The development of a National Service Framework 
for COPD in the UK has set goals to improve the quality 
and access to COPD services as well as to reduce inequali-
ties and health care utilization costs.172 A study by Lisspers 
et al in Sweden showed that incorporating specialist nurses 
in asthma/COPD clinics decreased AECOPD in patients 
without additional secondary specialist care.173 Research-
ers from Plymouth University in the UK are undertaking a 
project in several LMICs to improve access to health care 
to prevent and manage chronic lung diseases including 
nontraditional pulmonary rehabilitation clinics, smoking 
cessation programs, and involving local midwives.174 The 
project, FRESH AIR, will adapt and test innovative ways 
to implement evidence-based practice in the prevention, 
diagnosis, and treatment of chronic lung disease in several 
LMICs. A study in Pakistan plans to target low resource 
settings using various approaches such as providing COPD 
care in the existing tuberculosis clinics.175
Studies looking at the impact of telemedicine have been 
equivocal in improving access to health care and outcomes 
in COPD.176 Telemedicine is more challenging in low SES 
people for various reasons. For example, the poor and 
elderly tend to use cheaper, less “smart” phones, and there-
fore, technology may not be compatible with the COPD 
patients’ technological capabilities.
Educating more respiratory specialists, including 
minority providers, is needed as rural and poor areas 
lack pulmonary specialists in many countries. Little has 
been published regarding the geographic distribution of 
specialists and therefore availability of care for low SES 
COPD patients.8 The ATS, ERS, and Forum of Interna-
tional Respiratory Societies support better education and 
availability of providers available to COPD patients. They 
want to ensure that medical and other health care students 
are taught about the association between COPD and SES. 
Postgraduate education regarding disparities is also needed 
at multi- and interdisciplinary conferences for health care 
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providers, public health practitioners, health agencies, and 
others in every country to address SES and lung diseases 
in an ongoing basis.
Screening and diagnosis
Since the majority of people with undiagnosed COPD have 
low SES, undertaking population screening or case-finding in 
targeted communities or health care settings is desirable. There 
are a number of screening and case-finding questionnaires 
that can identify people at high risk of COPD.177–181 Although 
smoking history is always addressed, most do not include 
questions about BF or occupational exposures.183 A COPD 
screening questionnaire was developed in the People’s 
Republic of China, which included both smoking and expo-
sure to BF from cooking but did not include occupational 
exposures.181 The BOLD and PLANTINO studies’ question-
naires included occupational exposures and smoking history, 
but not BF.62,182 To make COPD case-finding or population 
screening most applicable globally, it is imperative to develop 
and validate such questionnaires that include all three major 
categories of COPD risk factors – tobacco, occupation, and 
BF exposures. In general, the sensitivity of such screening/
case-finding questionnaires can be improved with portable 
flow meters that measure FEV
1
 and FEV
6
.183
Diagnostic resources for COPD in LMICs are poor; 
therefore, diagnoses are often made on the basis of clinical 
features alone, which is a distinct limitation for a disease that 
by the strictest definition requires documentation of AO. One 
Chinese study did use discriminant function analysis, not 
relying on spirometry, by using nine patient characteristics 
including smoking history, occupation, and rural vs urban 
residence, to screen for COPD in impoverished areas. The 
sensitivity was reported to be ~90% based upon AO measured 
by spirometry. One study showed the benefits of screening 
for undiagnosed COPD in different socioeconomic practice 
settings.184
The WHO published specific guidelines to aid primary 
care providers in low-income populations for the diagnosis 
and management (Figure 2) of COPD.142 In situations where 
diagnostic spirometry is limited, WHO recommends to make 
a diagnosis based on age, clinical history (persistent respira-
tory symptoms and chronic productive cough), and exposure 
history (.1 ppd ×15 years). Although debatable, it was also 
recommended that peak flow meters can be used to determine 
AO reversibility and thus help differentiate between asthma 
and COPD. However, portable spirometers that can measure 
peak flows, FEV
1
, FEV
6
, and/or forced vital capacity are now 
fairly inexpensive.
Treatment
The care offered to low SES patients with chronic respiratory 
disease is not always based on research or best practices. 
Often, access to optimal COPD treatments, such as avail-
ability to primary and specialist providers, smoking ces-
sation counseling, supplemental oxygen, and noninvasive 
ventilation, is limited in these people. The WHO published 
guidelines for the treatment of asthma and COPD by primary 
care providers in resource-limited settings.142 It was designed 
to aid easy access and facilitate implementation in busy com-
munity clinics and small hospitals. It provides recommenda-
tions for acute and chronic management of COPD. Patient 
education regarding preventive measures such as stopping 
smoking tobacco products, use of well-ventilated areas for 
cooking and heating, as well as awareness about high-risk 
occupations is recommended. The recommended drug 
therapies are few and by most developed country’s standards 
would probably be considered to be suboptimal.
One important goal to optimally treat COPD patients is 
to properly diagnose and manage comorbidities common to 
this population. Early identification and optimal treatment of 
heart disease, lung cancer, depression, and obstructive sleep 
apnea can improve outcomes. Heart disease and lung cancers 
are more common in COPD, which more likely occur in low 
SES people. Cardio-selective B-blockers, when prescribed 
for some types of heart disease, reduce the overall mortality in 
COPD.185 Unfortunately, too often practitioners are reluctant 
to prescribe these agents for COPD, although the cardio-
selective agents have a low risk of worsening AO.186 These 
agents are available generically and are relatively affordable. 
In the US, low-dose chest CT screening has commenced in 
high-risk people to identify early lung cancer and decrease 
the associated mortality; however, this is quite expensive.187 
Obstructive sleep apnea occurs in COPD at about the same 
rate as the comparable patients in general population but 
is more common in low SES patients.188 Patients with co-
existing COPD and sleep apnea typically develop more 
severe oxygen desaturation during sleep and have worse 
outcomes.189 Treatment of severe obstructive sleep apnea is 
most effectively done with noninvasive ventilation, although 
costs may be prohibitive.
Efforts to educate the general public and COPD patients 
are sorely lacking, particularly for impoverished people. 
Only recently, education about COPD to the general public 
has been undertaken in the US, whereas much more has been 
done to educate the public about asthma. Education about 
smoking, BFs, and the disease COPD should start as early 
as primary schools; however, health literacy is a major issue 
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Management of exacerbation of COPD
Antibiotics: should be given for AECOPD (strong recommendation, very low-quality evidence)
Oral steroids: a short course of prednisolone is recommended for severe AECOPD (eg, prednisolone 30–40 mg for about 7 days 
(strong recommendation, very low-quality evidence) 
Inhaled beta agonists: higher doses of inhaled salbutamol should be administered via a nebulizer or spacer (strong recommendation, 
very low-quality evidence) 
Oxygen: if available, oxygen should be administered by a device that controls concentration of 24%–28% (strong recommendation, 
very low-quality evidence)
Intravenous aminophylline: based on the available evidence, IV aminophylline not recommended in AECOPD. Little evidence of 
benefit; any beneficial effect is likely small and outweighed by ADRs (strong recommendation, very low-quality evidence)
Stable management
Short-acting beta-agonists: are effective in improving symptoms in patients with stable COPD. Prescribe as required. No data to 
assess the optimum frequency of administration or the effect of regular administration. Oral B-agonists not recommended (weak 
recommendation, very low-quality evidence) 
Theophylline: unlikely that blood levels can be monitored in resource-constrained settings, only low doses of theophylline are 
recommended. Patients should be advised about ADRs (weak recommendation, very low-quality evidence) 
Oral corticosteroids (prednisolone): are ineffective in stable COPD except possibly in high doses when there are important side 
effects. On the basis of benefits and risks, oral steroids are not recommended for use in stable COPD (strong recommendation, very 
low-quality evidence) 
Inhaled steroids (beclomethasone): when given in high doses, there may be a small benefit from ICS; however, high doses are 
expensive for resource-poor countries and high doses have more ADRs, including pneumonia. Risks are unknown in areas where the 
prevalence of HIV and tuberculosis are high. Since the benefit is modest, the risk/benefit ratio is much higher than it is for asthma. The 
use of ICS for patients with stable COPD therefore cannot be justified. Not recommended (strong recommendation, very low-quality 
evidence)
Ipratropium bromide: when compared to regular short-acting beta agonists, short-term inhaled ipratropium bromide has small benefits 
in reducing symptoms and improving lung function. Currently, ipratropium preparations are more expensive than beta agonists, 
and there are no data to assess risk versus benefits of regular use over longer periods to recommend long-term regular use. Not 
recommended (weak recommendation, very low-quality evidence)
Figure 2 World Health Organization drug therapy guidelines for managing acute exacerbations of COPD and stable management in resource limited settings.
Note: Reprinted from World Health Organization. Prevention and control of non-communicable diseases: guidelines for primary health care in low-resource settings. 
Copyright 2012.142
Abbreviations: ADRs, adverse drug reactions; AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency 
virus; ICS, inhaled corticosteroid; IV, intravenous.
in some of these children and their families. Education about 
COPD and its risk factors should be culturally sensitive and 
at the appropriate education level for the target population. 
A study in a primary care setting showed that COPD patients 
with a high-school or less education, capable of communicat-
ing or writing, were able to be successfully educated about 
their disease.190
Poor access to medications and noncompliance are major 
factors that limit the optimal management of obstructive 
lung diseases.191,192 Identifying cost-effective drug therapy 
strategies will vary among different settings and countries; 
health care providers should explore what the options are in 
their local settings. Essentially, all evidence-based COPD 
medications are more limited in resource sparse settings and 
even the most basic medications have variable availability. 
This is true despite the overall cost-effectiveness of inter-
ventions such as smoking cessation counseling combined 
with drug therapy or maintenance drugs that can decrease 
AECOPD. It is well documented that maintenance medica-
tions for COPD can improve respiratory symptoms and 
quality of life and decrease AECOPD1 and that medication 
adherence can improve mortality.193 There is little defini-
tive data supporting that these medications can modify the 
course of COPD; however, it could be a function of identi-
fying phenotypes and genotypes with which drug therapies 
could slow down the progression of the disease and improve 
survival. Currently, interventions with the most mortality 
benefits relevant to COPD include 1) long-term supplemental 
oxygen, 2) smoking cessation, 3) lung transplantation, and 4) 
optimizing prevention or management of key comorbidities 
such as heart disease – the latter three include medications.
Annually, the WHO publishes an updated essential medi-
cine list that includes the most basic drug therapies relevant 
to the acute and chronic management of COPD.194 Even for 
these therapies, disadvantaged persons have substantial chal-
lenges in accessing and paying for COPD medications as well 
as being adherent with their therapies. The most basic drug 
therapy, albuterol, can account for a high portion of personal 
income in LMICS, often as much as several days wages.144 
In the US, drug costs can also be quite substantial for a person 
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living in poverty. In an advanced COPD patient, a triple 
drug regi men could cost nearly half of a monthly personal 
income without health insurance subsidies (Table 5). Even 
when subsidized by insurers, the poor often choose between 
basic living necessities vs appropriately using their prescribed 
COPD medications. One strategy in the US to decrease drug 
costs for retired or disabled COPD patients, covered by the 
federal Medicare insurance program, is to prescribe nebulized 
albuterol, ipratropium, formoterol, arformoterol, and/or 
budesonide if they fail the same drugs through an inhaler. 
Different settings may have resources available to uniquely 
help lower the drug costs.
An important contributor to unaffordability of COPD 
medications is the lack of generic versions for the majority of 
drugs used to chronically manage COPD. In contrast, many 
of the prominent maintenance medications for cardiovascular 
diseases and other major chronic diseases often have cheaper 
generic drugs. In the US, this is affected by Food and Drug 
Administration requirements for new “generic” inhalers. 
Somewhat extensive and expensive studies are mandated 
for generic inhalers by the US Food and Drug Administra-
tion, often taking years to bring to market. The European 
Medicines Agency has less strict requirements to bring a 
generic inhaler to the market. It has been suggested that 
regulatory agencies among different countries share and 
accept submitted pharmaceutical company dossiers among 
themselves through harmonizing regulations. This has been 
the major impediment toward declaring a “global worldwide 
reference product” that generic pharmaceutical companies 
could use in their development.119
It is well-documented that people with low SES have 
significantly worse medication adherence, including for 
COPD. There are multiple contributors including commercial 
availability, costs, and health behaviors that affect adherence. 
Medication adherence is a function of numerous factors, and 
in general people of a low SES tend to be the most noncom-
pliant.195 This is partially due to lack of resources in some 
people, however, occurs even in an insured indigent. In a study 
of a US health system in adults with health care insurance, it 
was found that medication adherence was poorest in people 
with low education level; and further patients with asthma or 
COPD had the worse adherence compared with chronic dis-
eases such as depression and diabetes mellitus.31 In 2006, one 
study found that tiotropium was used less frequently in people 
with low vs high SES (odds ratio =0.3),46 whereas in another 
study albuterol use was prescribed more often in highly pol-
luted areas where the poor live.131 An excellent review on 
access to essential medicines for obstructive lung diseases and 
related issues in disparate settings was published in 2015 by 
the Forum of International Respiratory Societies.196
Conclusion
Across the globe, COPD disproportionately affects ethnic 
minorities and low socioeconomic groups. Vulnerable popu-
lations have differential exposure to indoor and outdoor pol-
lution, occupational and environmental hazards, and tobacco 
smoke, which contribute to disparities in prevalence of COPD 
and outcomes. However, social determinants of health (ie, 
access to health care, education, economic stability, social 
and community context, and neighborhood/built environment) 
add an additional barrier to establishing health equity. Con-
sequently, interventions that are designed to improve health 
equity should be adapted for the socioeconomic and political 
context in which the vulnerable problems exist. Each setting, 
whether it is the individual clinic setting, health care system, 
community, region, and country, has its unique influences and 
resources that will determine the best approaches to lessen the 
burden of health disparities related to COPD. Whether it is at 
the health care provider–patient level, the health care organiza-
tion level, or societal level – it has been and will continue to be 
a challenge to lessen the disparities associated with COPD and 
SES, if no other reason, the availability of adequate resources. 
No one sector will solve the issues with disparities regarding 
COPD. Eventually, COPD will be a disease of predominantly 
the low SES segment of the population, whether caused by 
tobacco or biomass or occupation. The question is going to 
be how significant a role the disease plays, which depends on 
resources, programmatic approaches, and individual health 
Table 5 Drug costs relative to days of work in low-income people in the US 
Measure Albuterol MDI 
(200 inhalations)
ICS/LABA inhalera LAMA inhalera
 
Albuterol + ICS/
LABA + LAMA
Retail drug costsb $55.00 $340.00 $320.00 $715.00
Days of work required to pay for 
medication(s) using ~ minimum wagec
0.86 days 5.3 days 5 days 11.2 days
Notes: aOne month supply. bApproximate retail costs with no subsidies were obtained from www.goodrx.com. Accessed February 1, 2016.197 cAnnual income of $16,640 
(based on a minimum wage salary of $8/hour at 40 hours/week).
Abbreviations: MDI, metered dose inhaler; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting antimuscarinic agent.
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care and public health providers and societies. However, when 
it comes to health care costs, being poor is expensive. We 
have largely “diagnosed the syndrome of health disparities 
in COPD”, and evidence-based strategies that address SES 
are greatly needed to decrease disease burden.
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